"10.1371_journal.pone.0034723","plos one","2012-04-11T00:00:00Z","Katharina B√∂ckl; Jens Wild; Simon Bredl; Kathrin Kindsm√ºller; Josef K√∂stler; Ralf Wagner","Institute of Medical Microbiology, University of Regensburg, Regensburg, Germany; Geneart AG/Life Technologies, Regensburg, Germany","Conceived and designed the experiments: KB JW SB KK JK RW. Performed the experiments: KB JW SB. Analyzed the data: KB JW SB. Wrote the paper: KB JW RW.","The authors declare that no competing interests exist. Simon Bredl and Kathrin Kindsm√ºller are former members of the group of Ralf Wagner and left the Institute after completing the experiments presented in this manuscript. The company addresses represent their present working addresses. Ralf Wagner is founder and CEO/CSO of GeneArt. He is also Vice President at Life Technologies and as such representing the Synthetic Biology Business Unit within Life technologies. Ralf Wagner is employee of Life Technologies as well as the University of Regensburg. GeneArt and Life Technologies hold IP on the some RNA and codon optimized HIV CN54 genes, which were analyzed in this study. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","04","Katharina B√∂ckl","KB√",6,FALSE,6,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
